Morning Breakouts

Latest California Healthline Stories

Legislature’s Approval Ratings Hit All-Time Low, Poll Finds

A Field Poll released on Tuesday finds that only 10% of California’s registered voters approve of the state Legislature’s performance, while 80% disapprove. The latest approval ratings are the lowest the Legislature has received since the poll began in 1983. Mark DiCamillo, director of the Field Poll, said the Legislature’s low approval ratings likely stem from lawmakers’ record-breaking delay in passing a budget for the current fiscal year. San Francisco Chronicle.

Sebelius: Reform Providing Needed Oversight of Insurers

Recent criticism of HHS — which has been accused of “thuggery” and “Soviet tyranny” — is “objectionable” because it means that such critics “believe that any oversight of the insurance industry is too much and that consumers would be better off in a system where they have few rights or protections,” HHS Secretary Kathleen Sebelius writes in a Wall Street Journal opinion piece.  Sebelius continues, “If critics really want to go back to the days when insurance companies ran wild with no accountability, they should have the courage to say so openly instead of hiding behind distracting attacks.” Wall Street Journal.

Editorial Criticizes Campaign Against Insurance Exchange

Anthem Blue Cross and the California Chamber of Commerce “are spreading a trio of fear-mongering falsehoods” against legislation that would create the California Health Benefit Exchange, a Sacramento Bee editorial states. Anthem and the chamber’s “bill-killing effort” says that the legislation would “create a new branch of government,” would expose “taxpayers to costs associated with ‘fraud, inefficiency or abuse'” and would “have broad authority to levy fees on health insurance plans, hurting consumers,” all of which are untrue, according to the Bee. Sacramento Bee.

Court Extends Temporary Stay on Stem Cell Funding

On Monday, a three-judge panel in the U.S. Court of Appeals in Washington, D.C., extended a temporary stay on a U.S. district court judge’s preliminary injunction on federal funding for embryonic stem cell research, allowing U.S. researchers to continue work on federally approved projects. The stay remains in place until a final ruling is issued on the legality of federally funding such research, which may not arrive for several weeks or months. AP/Boston Globe, Wall Street Journal.